XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Sees Significant Drop in Short Interest

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) saw a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 10,999 shares, a drop of 55.2% from the July 30th total of 24,556 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 5,965 shares, the short-interest ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

XTL Biopharmaceuticals Trading Up 3.6%

NASDAQ XTLB traded up $0.09 during trading on Monday, hitting $2.56. 433 shares of the company traded hands, compared to its average volume of 808,688. XTL Biopharmaceuticals has a 12 month low of $2.01 and a 12 month high of $10.28. The business has a fifty day simple moving average of $2.79 and a 200 day simple moving average of $2.72. The company has a market capitalization of $5.63 million, a P/E ratio of -4.00 and a beta of 1.46.

XTL Biopharmaceuticals (NASDAQ:XTLB) last issued its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of ($0.26) million during the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.